FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely ophthalmology, and may be used for treating dry eye syndrome and recovered function of lachrymal fluid secretion in a mammal. For this purpose, a composition containing a pharmaceutically effective amount of a Janus kinase 3 inhibitor of the following structure is introduced in a mammal: 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d] pyrimidin-4-yl) amino] piperidin-1-yl}-3-oxopropionitryl.
EFFECT: introduction of the Janus kinase 3 inhibitor enables considerable increase of the secreted lachrymal fluid volume.
11 cl, 2 tbl, 6 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS | 2012 |
|
RU2618673C2 |
| NEW COMPOUNDS OF PYRROLOPYRIMIDINE AS INHIBITORS OF PROTEIN KINASES | 2013 |
|
RU2645672C2 |
| COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF DRY EYES | 2019 |
|
RU2763423C1 |
| PYRROLOPYRIMIDINE COMPOUNDS AND APPLICATION THEREOF | 2011 |
|
RU2563644C2 |
| THERAPEUTIC ANTIDIABETIC AGENT | 2006 |
|
RU2438671C2 |
| NEW CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | 2017 |
|
RU2770727C2 |
| 5-(7H-PYRROLO[2,3-d]PYRIMIDINE-4-YL)-5-AZASPIRO[2.5]OCTANE-8-CARBOXYLIC ACID DERIVATIVES AS NEW JAK-KINASE INHIBITORS | 2018 |
|
RU2761626C2 |
| PYRROLOPYRIMIDINES USED AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2434871C2 |
| SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
| TRICYCLIC JANUS KINASE 1 INHIBITORS, COMPOSITIONS, METHODS OF PRODUCTION AND USE THEREOF | 2019 |
|
RU2824349C2 |
